Kenrick Ng

Research Interests: Solid Tumour Oncology; Genitourinary Cancer; Lung Cancer; Cancer Immunology; Cardio-Oncology; Predictive Biomarkers; Disparities in Cancer Care

Biography: Dr. Kenrick Ng obtained his medical degree from the University of Cambridge in 2012. He furthered his postgraduate training in Central London hospitals, obtaining a Postgraduate Diploma in Medical Education in 2014, Membership of the Royal College of Physicians in 2015 and Speciality Certificate in Medical Oncology in 2020. He is due to complete a PhD in Tumour Immunology in the UCL Cancer Institute under a Cancer Research UK Clinical Research Training Fellowship, while concurrently acting as Honorary Clinical Research Fellow in Early Phase Clinical Trials in the NIHR UCLH Clinical Research Facility. 
He is on the advisory board of the journal Oncology and Therapy, and has been subinvestigator of research grants from the UK Medical Research Council and the Cancer Research UK Early Detection Scheme. He has published more than 15 first author peer-reviewed articles and book chapters, and co-authored many others. His research work in cancer has been awarded with the prestigious Helen Patterson Research Registrar Award and ASCO Conquer Cancer Foundation Merit Award, and he has also supervised projects which have won the prestigious Sylvia Lawler Oncology Prize from the Royal Society of Medicine.

Websitehttps://www.researchgate.net/profile/Kenrick-Ng

Selected publications:
K Ng, K Vinnakota, A Sharma, J Kelly, P Dasgupta, N Vasdev Urinary Biomarkers to Mitigate Diagnostic Delays of Bladder Cancer in the COVID-19 era; Nature Reviews Urology, 2020

K Ng, P Wilson, K Mutsvangwa, L Hounsome, J Shamash Overall survival of black and white men with metastatic castration resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England; Prostate Cancer and Prostatic Diseases, 1-7, 2021

Gjafa E*, Ng K*, Grunewald T, Galazi M, Skyllberg E, Wilson P, Alifrangis C, Shamash J Neutropenic Sepsis Rates in Patients Receiving Bleomycin, Etoposide, and Cisplatin Chemotherapy using Olanzapine and Reduced Doses of Dexamethasone Compared to a Standard Antiemetic Regimen; BJU International, 127(2): 205-211